



**AGL** 2022

**51st GLOBAL CONGRESS ON MIGS**

December 1–4, 2022 | Gaylord Rockies Resort and Convention Center | Aurora, Colorado

# SYLLABUS

## Surgical Tutorial 2: Tubal Disease

SCIENTIFIC PROGRAM CHAIR  
ANDREW I. SOKOL, MD

HONORARY CHAIR  
CHARLES MILLER, MD

PRESIDENT  
MAURICIO S. ABRÃO, MD, PHD

## Table of Contents

Financial Disclosures .....	3
Course Program: Course Description, Learning Objectives, Course Outline .....	4
The Assessment of Tubal Patency and Health, Falloposcopy C. Harrity .....	5
Surgical Interventions Including Salpingectomy (before IVF), Tubal Cannulation, Distal Tuboplasty B. Bhagavath .....	10
Tubal Anastomosis M.P. Milad.....	15
Cultural and Linguistic Competency & Implicit Bias .....	18

## **Disclosure of Relevant Financial Relationships**

As an ACCME accredited provider, AAGL must ensure balance, independence, and objectivity in all CME activities to promote improvements in health care and not proprietary interests of an ineligible company. AAGL controls all decisions related to identification of CME needs, determination of educational objectives, selection and presentation of content, selection of all persons in a position to control content, selection of educational methods, and evaluation of the activity. Course chairs, planning committee members, faculty, authors, moderators, and others in a position to control the content of this activity are required to disclose all financial relationships with ineligible companies. All relevant financial relationships are appropriately mitigated, and peer review is completed by reviewers who have nothing to disclose. Learners can assess the potential for commercial bias when disclosure, mitigation of conflicts of interest, and acknowledgment of commercial support are provided prior to the activity. Informed learners are the final safeguards in assuring that a CME activity is independent from commercial bias. We believe this mechanism contributes to the transparency and accountability of CME.

Asterisk (\*) denotes no financial relationships to disclose.

## **PLANNER DISCLOSURE**

**The following members of AAGL have been involved in the educational planning and/or review of this course (listed in alphabetical order by last name).**

Linda J. Bell, Admin Support, AAGL\*

Linda D. Bradley, MD, Medical Director, AAGL\*

Erin T. Carey, MD, MSCR

Honorarium: Med IQ

Research Funding: Eximis

Mark W. Dassel, MD\*

Linda Michels, Executive Director, AAGL\*

Vadim Morozov, MD

Speaker: AbbVie

Consultant: Medtronic, Lumenis

Erinn M. Myers, MD

Speakers Bureau: Intuitive Surgical

Amy J. Park, MD

Speaker: Allergan

Nancy Williams, COO, CME Consultants\*

Harold Y. Wu, MD\*

Magdy P. Milad, MD, MS – Stock: Intuitive; Research

Grants: Hologic, Storz; Consultant: Baxter; Myovant;

Doximity

## **SCIENTIFIC PROGRAM COMMITTEE**

Andrew I. Sokol, MD - Medical Legal Defense: Johnson & Johnson

Angela Chaudhari, MD - Consultant: Johnson & Johnson  
Cara R. King, DO\*

Mario Malzoni, MD – Consultant: KARL STORZ

Jessica Opoku-Anane, MD, MS – Consultant: Boston Scientific; Myovant Sciences; AbbVie

Shailesh P. Puntambekar, MD, PHD\*

Frank F. Tu, MD, MPH\*

Jonathon M. Solnik, MD – Consultant: Olympus; Medtronic; Stockholder: Field Trip Health, Inc.; Felix Health

Linda D. Bradley, MD, Medical Director\*

Linda Michels, Executive Director, AAGL\*

## **FACULTY DISCLOSURE**

**The following have agreed to provide verbal disclosure of their relationships prior to their presentations. They have also agreed to support their presentations and clinical recommendations with the “best available evidence” from medical literature (in alphabetical order by last name).** Bala Bhagavath, MD – Contracted Research: PI for Hologic; Femasys; Myovant  
Conor Harrity, FRCOG, FACOG, FRCPI\*  
Magdy P. Milad, MD, MS – Stock: Intuitive; Research Grants: Hologic, Storz; Consultant: Baxter; Myovant; Doximity

## **Surgical Tutorial 2: Tubal Disease**

***Chair:*** Magdy P. Milad, MD, MS

***Faculty:*** Bala Bhagavath, MD, and Conor Harrity, FRCOG, FACOG, FRCPI

### **Course Description**

Globally, tubal disease remains one of the most common causes of infertility. While assisted reproductive technologies are becoming more widely available, in many parts of the world, due to resources or financial constraints, patients may only have access to surgical interventions. Unfortunately, the majority of recently trained subspecialists have little exposure to tubal assessment and the tenets of tubal surgery. This course will review the assessment of tubal anatomy, patency and internal architecture, and explore the surgical approaches to tubal factor infertility from salpingectomy to tubal anastomosis. Additionally, we will review fallopscopy as an emerging method of evaluating the luminal milieu

### **Learning Objectives**


*At the conclusion of this course, the participant will be able to:* 1) Interpret sono and radiologic HSG images of tubal occlusion; 2) Discuss many of the important tenets of tubal surgery; and 3) Hypothesize the role of fallopscopy in assessing for disease.

### **Course Outline**

2:00 pm	Welcome, Introduction and Course Overview	M.P. Milad
2:05 pm	The Assessment of Tubal Patency and Health, Fallopscopy	C. Harrity
2:20 pm	Surgical Interventions Including Salpingectomy (before IVF), Tubal Cannulation, Distal Tuboplasty	B. Bhagavath
2:35 pm	Tubal Anastomosis	M.P. Milad
2:50 pm	Questions & Answers	All Faculty
3:05 pm	Adjourn	

# Assessment of Tubal Patency and Health

Dr Conor Harrity FRCOG FACOG FRCPI  
MIGS/REI, Beaumont and Rotunda Hospitals  
FMIGS APD, Honorary Senior Lecturer, RCSI University  
Medical Director, First IVF



## Disclosure

I have no financial relationships to disclose




## Objectives

- Understand Tubal Function and Anatomy
- Evaluate Tests of Tubal Patency
- Rationale for modality choice
- Diagnosis of Tubal Pathology



## Tubal Function

- Conduit
  - Sperm Transit
- Reservoir
- Fertilisation
- Embryo Migration
  - Cilia
  - Tubal fluid
- Incubator
  - Cleavage





## Anatomy

- Infundibulum
    - Fimbriae, oocyte pickup
  - Ampulla
    - Most Plicae
    - Capacitation
    - Fertilisation
  - Isthmus
    - Sperm reservoir
  - Intramural
- 60% non-ciliated epithelial (secretory) cells  
• Percentage differs between regions (Pedrero-Badillo et al., 2013).



## Structure

- Endosalpinx
  - Ciliated epithelial cells
  - Nonciliated secretory epithelial cells
- Lamina propria
  - Fibroblasts
  - Immune
  - Progenitor cells
    - Lgr5-positive cells for tubal epithelial cell regeneration (Ng et al, 2014; Snegovskikh et al, 2014)
- Mucosal layer:
  - dense internal folds
  - increase surface area
  - high secretory rate






## Assessment (Non-Invasive)

### Hysterosalpingogram (HSG)

- Diagnostic
  - XR
  - WSCM
  - OSCM
- MRI
- Therapeutic
  - Tubal Cannulation

### USS

- 2D/3D
- HyCoSi
- Foam



## HSG Contrast Media

### OSCM

- Iodinated ethyl esters of the fatty acids of poppy seed oil (Lipiodol; Guerbet)
- Use for HSG was first described in 1925
- Until the 1950s predominant contrast material used
- Check TFTs before use

### WSCM

- Lower anaphylaxis risk
- Avoids concerns related to venous intravasation of embolic consequences

ULTRASOUND  
in Obstetrics & Gynaecology



Systematic Review | Free Access

Effectiveness on fertility outcome of tubal flushing with different contrast media: systematic review and network meta-analysis

- Wang et al 2019
  - 14 RCTs (n=3852)
  - OR for clinical pregnancy within 6/12 = 1.67 (95% CI, 1.38–2.03)



## Diagnostic Accuracy


Test*	Sensitivity (%)	Specificity (%)
HSG (50, 51)	65–81	75–83
HyCoSy with air-saline (34)	76.1	79.4
HyCoSy with microbubble contrast material (52)	91	95
3D or 4D HyCoSy with microbubble contrast material (52)	95	94
HyFoSy (35)	87.5	100
Virtual CT HSG (53)	100	86
MR HSG (52, 54)	100	82–93

Grigovich M et al. Evaluating Fallopian Tube Patency: What the Radiologist Needs to Know. RadioGraphics 2021; 41:1876–1896




## Assessment

- Laparoscopy
  - Assessment
  - Chromopertubation
  - Salpingoscopy
- Hysteroscopy
  - Osteal Peristalsis
  - Bubble Suction
  - Falloposcopy



## Which Test

- Low-risk patients
  - one-stop comprehensive USS + HyCoSy
- Fluoroscopic HSG
  - Suspicion of adhesions, pre-existing tubal disease, adenomyosis
- Unexplained subfertility <38 years
  - HSG with OSCM
  - higher pregnancy rates and live births (H2OIL study)
- MR HSG
  - Simultaneous assessment of tubal patency and suspected pelvic
  - Congenital anomalies
- Laparoscopy
  - Pre-existing conditions (PID, endometriosis)
  - Hydrosalpinx
  - Chronic pelvic pain




## Case 1

- 38, p1
  - CS, 5 years ago
- 4 years 2o SF
- PMHx:
  - HIV +ve
  - 4cm Fibroid
- AMH 2.9
- SA NAD

## Options

1. HyCoSi
  - AFC, Fibroid
  - Not available in Public hospital
  - Unable to fund Privately
2. HSG
  - Rt Distal Occlusion
  - Lt Proximal Occlusion
3. Laparoscopy



## Plan




1. Rt Tube
  - Salpingectomy vs Distal Neosalpingostomy
    - Financial
    - MHx
    - Salpingostomy
2. Endometriosis
3. Fibroid
  - Cavity
    - Hysteroscopy

## Case 2

- 32 p0, TTC x 4 yrs
- PMHx:
  - CPP
  - Laparoscopic ovarian cystectomy x 3
    - Histology:
      - Follicular cysts
      - No endometriosis
- AMH 6.9 pmol/L-1, SA NAD
- IVF → Failed ET x 2 (2 D5 remain)
- Cycle USS:
  - ?Rt Hydrosalpinx
  - Referred for Salpingectomy

## Options

- Tubal Assessment
  - HSG
  - HyCoSy
  - MRI
  - Laparoscopy
- Questions
  - Treatment
  - Contralateral Tube
  - CPP



## Plan

- Salpingectomy vs Salpingostomy
  - Chronic PID
    - Residual Ectopic Risk
  - IVF Outcome
- Lt Tube
  - Pt Consent
    - Conservation unless essential



## References

- Pedrero-Badillo F, Anaya-Hernández A, Corona-Quintanilla DL, Castelaín F, Pacheco P, Martínez-Gómez M, Cuevas E. Morphohistological characteristics of rabbit oviduct: a proposal for a single regionalization. *Anim Reprod Sci*. 2013 Dec;143(1-4):102-11.
- Ng A, Tan S, Singh G, Rizk P, Swathi Y, Tan TZ, Huang RY, Leushacke M, Barker N. Lgr5 marks stem/progenitor cells in ovary and tubal epithelia. *Nat Cell Biol*. 2014 Aug;16(8):745-57.
- Snegovskikh V, Mutlu L, Massasa E, Taylor HS. Identification of putative fallopian tube stem cells. *Reprod Sci*. 2014 Dec;21(12):1460-4.
- Wang R, van Welle N, van Rijswijk J, Johnson NP, Norman RJ, Dreyer K, Mijatovic V, Mol BW. Effectiveness on fertility outcome of tubal flushing with different contrast media: systematic review and network meta-analysis. *Ultrasound Obstet Gynecol*. 2019.
- Grigovich M et al. Evaluating Fallopian Tube Patency: What the Radiologist Needs to Know. *RadioGraphics* 2021; 41:1876-1896
- Dreyer K et al. Oil-Based or Water-Based Contrast for Hysterosalpingography in Infertile Women. *N Engl J Med* 2017; 376:2043-2052



# Surgical Interventions – Salpingectomy (before IVF), Tubal Cannulation, Distal Tuboplasty

Bala Bhagavath, MD  
Professor of OBGYN  
Director, Division of REI

# Disclosures

- Contracted Research – PI for Hologic, Femasys and Myovant

# Salpingectomy before IVF

# Does hydrosalpinx impact Live Birth?

2. Live birth rate per IVF cycle started\*

Study or Subgroup	Salpingectomy	US aspiration	Total	Total	Risk Ratio	Risk Ratio
	Events	Events			M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
<b>1.1.1 Randomized controlled trials</b>						
Fuqua 2015	29	30	59	59	1.52 [0.54, 2.40]	
Subtotal (95% CI)	29	30	59	59	1.52 [0.54, 2.40]	
Total events	29	30				
Heterogeneity: Not applicable						
Test for overall effect: Z = 1.70 (P = 0.09)						
<b>1.1.2 Observational studies</b>						
Song 2017	43	21	109	109	2.31 [1.49, 3.50]	
Subtotal (95% CI)	43	21	109	109	2.31 [1.49, 3.50]	
Total events	43	21				
Heterogeneity: Not applicable						
Test for overall effect: Z = 3.74 (P < 0.0002)						
<b>Total (95% CI)</b>						
Total events	72	40	168	168	1.58 [1.49, 2.08]	
Heterogeneity: Chi² = 1.52, df = 1 (P = 0.22), I² = 34%						
Test for overall effect: Z = 3.30 (P < 0.0007)						
Test for subgroup differences: Chi² = 1.52, df = 1 (P = 0.22), I² = 34.2%						

Volodarsky-Perel A et al. Treatment of hydrosalpinx in relation to IVF outcome: a systematic review and meta-analysis. Reprod Biomed Online. 2019 Sep;39(3):413-432.

# Does hydrosalpinx cause biochemical pregnancy?

Study	Hydrosalpinx		No Hydrosalpinx		Risk Ratio	
	Biochemical Pregnancies	Pregnancies	Biochemical Pregnancies	Pregnancies	Random, 95% CI	Random, 95% CI
Altman 1996	0	1	0	24	Not estimable	
Anderson 1994	11	20	06	332	3.26 [2.05, 5.16]	
Barnard 1999	17	59	04	566	2.55 [1.65, 4.08]	
Blazer 1987	6	45	16	132	1.10 [0.48, 2.66]	
Freeman 1996	4	18	17	166	2.77 [0.82, 9.70]	
Murray 1999	0	4	0	56	Not estimable	
<b>Total (95% CI)</b>		147		1274	3.36 [1.03, 10.80]	
Total events	38		153			
Heterogeneity: Tau² = 0.08; Chi² = 5.26, df = 3 (P = 0.15); I² = 43%						
Test for overall effect: Z = 4.02 (P < 0.0001)						

FIGURE 6 Meta-analysis of studies comparing biochemical pregnancy loss in women who had a hydrosalpinx to women who did not have a hydrosalpinx.

Harb H et al. Hydrosalpinx and pregnancy loss: a systematic review and meta-analysis. Reprod Biomed Online. 2019 Mar;38(3):427-441.

# Does hydrosalpinx cause ectopic pregnancy?

Study	Hydrosalpinx		No Hydrosalpinx		Risk Ratio	
	Ectopic Pregnancies	Pregnancies	Ectopic Pregnancies	Pregnancies	Random, 95% CI	Random, 95% CI
Altman 1996	0	1	0	24	4.77 [2.24, 12.60]	
Anderson 1994	5	20	22	332	3.71 [0.85, 8.91]	
Barnard 1999	6	59	16	566	3.00 [1.54, 7.08]	
Blazer 1987	4	45	11	132	1.07 [0.36, 3.16]	
Cohen 1999	2	6	0	49	35.71 [1.86, 688.87]	
Flannery 1996	2	18	4	57	1.59 [0.35, 7.96]	
Freeman 1996	1	18	7	166	1.39 [0.37, 10.15]	
Katz 1996	1	16	30	465	0.97 [0.14, 6.97]	
Murray 1999	4	4	1	56	34.29 [6.46, 176.40]	
Ng 1987	3	9	0	11	6.40 [0.49, 144.04]	
Storaka 1986	2	27	0	30	5.68 [0.28, 115.42]	
Wu 2016	0	9	0	327	3.69 [0.12, 104.90]	
<b>Total (95% CI)</b>		333		2916	3.27 [1.05, 10.20]	
Heterogeneity: Tau² = 0.46; Chi² = 18.71, df = 11 (P = 0.07); I² = 41%						
Test for overall effect: Z = 3.40 (P < 0.0005)						

FIGURE 7 Meta-analysis of studies comparing ectopic pregnancy in women who had a hydrosalpinx to women who did not have a hydrosalpinx.

Harb H et al. Hydrosalpinx and pregnancy loss: a systematic review and meta-analysis. Reprod Biomed Online. 2019 Mar;38(3):427-441.

## Does hydrosalpinx cause pregnancy Loss?




FIGURE 4 Meta-analysis of studies comparing clinical pregnancy loss in women who had a hydrosalpinx to women who did not have a hydrosalpinx.

Harb H et al. Hydrosalpinx and pregnancy loss: a systematic review and meta-analysis. Reprod Biomed Online. 2019 Mar;38(3):427-441.

## Does removal of hydrosalpinx affect pregnancy loss?





FIGURE 3 Meta-analysis of studies comparing total pregnancy loss in women who had treatment (all interventions) for hydrosalpinx to women who did not undergo treatment for hydrosalpinx subgrouped according to study type.


Harb H et al. Hydrosalpinx and pregnancy loss: a systematic review and meta-analysis. Reprod Biomed Online. 2019 Mar;38(3):427-441.

## Does type of management of hydrosalpinx affect pregnancy loss?



Harb H et al. Hydrosalpinx and pregnancy loss: a systematic review and meta-analysis. Reprod Biomed Online. 2019 Mar;38(3):427-441.

## Does type of management of hydrosalpinx affect ectopic pregnancy?



Harb H et al. Hydrosalpinx and pregnancy loss: a systematic review and meta-analysis. Reprod Biomed Online. 2019 Mar;38(3):427-441.

## Conclusion regarding hydrosalpinx

Management of hydrosalpinx by salpingostomy or salpingectomy decreases biochemical pregnancies and pregnancy loss, possibly ectopic pregnancies and increases ongoing pregnancy and live birth rates

## Tubal Cannulation

## Does proximal tubal cannulation affect Live Birth Rate?




Figure 7 Live birth rate after tubal cannulation for proximal tubal obstruction.

De Silva PM et al. Fallopian tube catheterization in the treatment of proximal tubal obstruction: a systematic review and meta-analysis. Hum Reprod. 2017 Apr 1;32(4):836-852. doi: 10.1093/humrep/dex022. PMID: 28184438.

## Does proximal tubal cannulation affect ectopic pregnancy rate?




Figure 8 Ectopic pregnancy rate after tubal cannulation for proximal tubal obstruction.

De Silva PM et al. Fallopian tube catheterization in the treatment of proximal tubal obstruction: a systematic review and meta-analysis. Hum Reprod. 2017 Apr 1;32(4):836-852. doi: 10.1093/humrep/dex022. PMID: 28184438.

## Distal Tuboplasty

## Natural pregnancy rates after salpingostomy




Figure 2 Natural pregnancy rates after salpingostomy treatment for hydrosalpinx.

Chu J et al. Salpingostomy in the treatment of hydrosalpinx: a systematic review and meta-analysis. Hum Reprod. 2015 Aug;30(8):1882-95.

## Natural pregnancy rates after salpingostomy




Figure 4 Cumulative natural pregnancy rates after salpingostomy treatment for hydrosalpinx.

Chu J et al. Salpingostomy in the treatment of hydrosalpinx: a systematic review and meta-analysis. Hum Reprod. 2015 Aug;30(8):1882-95.

## Natural pregnancy rates after salpingostomy




Figure 6 Live birth rates after salpingostomy treatment for hydrosalpinx.

Chu J et al. Salpingostomy in the treatment of hydrosalpinx: a systematic review and meta-analysis. Hum Reprod. 2015 Aug;30(8):1882-95.

## Ectopic pregnancy rates after salpingostomy




Figure 7 Ectopic pregnancy rate after salpingostomy treatment for hydrosalpinx.

Chu J et al. Salpingostomy in the treatment of hydrosalpinx: a systematic review and meta-analysis. Hum Reprod. 2015 Aug;30(8):1882-95..

## Miscarriage rates after salpingostomy





Figure 8 Miscarriage rates after salpingostomy treatment for hydrosalpinx.

Chu J et al. Salpingostomy in the treatment of hydrosalpinx: a systematic review and meta-analysis. Hum Reprod. 2015 Aug;30(8):1882-95..

## Salpingitis Isthmica Nodosa



## Classification of SIN

Histological classification of SIN.

Grade I	The presence of lumens with tubal epithelium within the myosalpinx in an adequate cross section of the tube, through to the inner one-third of the myosalpinx
Grade II	Lesions extended through the inner two-third of the myosalpinx
Grade III	Lesions showed full extension through the myosalpinx to a subserosal location


## Management of SIN

- Most practical management – ART
- If ART not possible or not acceptable
  - Selective catheterization of proximal tube
    - 5/22 (23% pregnant with 4.5% ectopic) (Houston and Machan)
    - 20/65 (31% pregnant with 5% ectopic) (Thurmond)
  - Resection of affected segment and anastomosis of cut ends
    - 56% IUP and 11% Ectopic (Schmidt et al)





Bolaji et al. An odyssey through salpingitis isthmica nodosa.




Essure

# Essure related IVF outcomes

Table 3. Vaccination-related and *in vitro* fertilization (IVF)-related outcomes[illegible]

Data missing  
 No initial infection was confirmed in the remaining patients.  
 Not applicable in a third pregnancy  
 One woman was 3 months pregnant at time of publication.  
 Does not include the spontaneous pregnancy in one patient after infection of breast before IVF embryo transfer could be done.  
 No applicability in one embryo transfer  
 Recurrent of placenteritis in one woman on second attempt.  
 Concomitant to all women  
 Included one fetal death at 27 weeks of gestation.  
 Only data of patients on study visit 10. Data<sup>10</sup> included  
 No data confirmation by ultrasound  
 These women had developed asymptomatic embryo transfer before IVF have done. Two women had not yet performed IVF, while one woman spontaneously conceived before IVF



# Tubal Anastomosis

Magdy Milad, MD, MS

Albert B Gerbie Professor  
Division Chief, MIGS  
Medical Director, Center for Complex Gynecology  
Northwestern Medicine  
Chicago, IL, USA



## Disclosures

- Stock
  - Intuitive
- Research grants
  - Hologic
  - Storz
- Consultant
  - Baxter
  - Myovant Sciences
  - Doximity
- Medical expert

## Objectives

- To review the history of tubal ligation and incidence of regret
- To improve understanding of the preoperative assessment
- To demonstrate surgical approaches to tubal anastomosis
- To discuss the factors that influence success of tubal anastomosis

## History of Tubal Sterilization


- 1823 - Blundell first suggested tubal ligation for sterilization before the Medical Society of London.
- 1880 - Lungren (Toledo, OH) was first to perform a tubal ligation.
- 1895 - Dührssen used a double ligature and was the first to perform tubal ligation via colpotomy.
- 1897 - Kehrer and Buettner divided the tubes between the sutures.
- 1919 - Madlener crushed and ligated the tubes with nonabsorbable suture.
- 1924 - Irving published his method in which the proximal portion of the severed tube is buried.
- 1930 - Pomeroy technique published in the NY State J of Med posthumously by colleagues.
- 1936 - Bosch (Switzerland) performed the first laparoscopic tubal occlusion.
- 1940s - Uchida developed his technique.
- 1960s - Laparoscopic unipolar followed by bipolar electrocoagulation of the fallopian tube.
- 1973 - Hulka described a spring clip that could be applied laparoscopically.
- 1981 - Filshie introduced a titanium and silicone clip widely used in Europe.

Tubal Sterilization, Medscape, Jul 26, 2021, Chief editor: Robert K Zurawin, MD

## Common Types of Tubal Ligation




## Tubal Ligation Failure Based on Type




Bartz D, Greenberg JA. Sterilization in the United States. Rev Obstet Gynecol. 2008;1(1):23-32

## Cumulative Regret Rate in the US



Bartz D, Greenberg JA. Sterilization in the United States. Rev Obstet Gynecol. 2008;1(1):23-32

## Overall Proportion with Regret Based on Age



Wolters Kluwer

Danvers A, Evans TA. Obstet Gynecol 2022;139(3):433-439.

## Risk Factors for Regret

- Less than 30 years old

US Collaborative Review of Sterilization "CREST". 1999;93:889-95.  
Danvers A, Evans TA. Obstet Gynecol 2022;139(3):433-439.

## Preop Workup

- Obtain previous operative and pathology report
- Hysterosalpingogram
- Semen analysis
- AMH level

## Surgical Principles

- Gentle tissue handling
- Remove adhesions
- Freshen ends and identify lumen
- Confirm proximal patency
- Reapproximate mesosalpinx
- Reapproximate lumen with fine suture (microsurgical)
- Confirm distal spill

## Surgical Access

- Laparotomic
- Laparoscopic
- Robotic
  - Single site
  - Multiport

## Surgical Videos

## Overall Success of Tubal Anastomosis

- 37 studies 10,689 women.
- No randomized controlled trials.
- Most studies were retrospective cohort studies of a moderate quality.
- The pooled pregnancy rate was 42-69%.
- The reported ectopic pregnancy rate was 4-8%.
- The only prognostic factor affecting the chance of conception was female age.
- The surgical approach (i.e., laparotomy [microscopic], laparoscopy or robotic) had no impact on the outcome.
- For older women, IVF could be a more cost-effective alternative.

Jacoba A H van Seeters JAH, Chua SJ, Bol BWJ, Koks CAM. Tubal anastomosis after previous sterilization: a systematic review. Hum Reprod Update 2017;1,23(3):358-370.

## Conclusions

1. Tubal ligation regret is common, particularly at a younger age
2. Preoperative workup and counseling is essential
3. Age is the best predictor of success followed by the use of microsurgical technique and the length of the tube postop.
4. Patients should be counseled and monitored for tubal pregnancy.

## References

1. Tubal Sterilization, Medscape, Jul 26, 2021, Chief editor: Robert K Zurwain, MD
2. Bartz D, Greenberg JA. Sterilization in the United States. Rev Obstet Gynecol. 2008;1(1):23-32
3. Danvers A, Evans TA. Obstet Gynecol 2022;139(3):433-439.
4. Jacoba A H van Seeters JAH, Chua SJ, Bol BWJ, Koks CAM. Tubal anastomosis after previous sterilization: a systematic review. Hum Reprod Update 2017;1,23(3):358-370.
5. Peterson HB, Xia Z, Hughes JM, et al. The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization. Am J Obstet Gynecol. 1996;174:1161-1170.
6. Hillis SD, Marchbanks PA, Tylor LR, et al. Poststerilization regret: findings from the United States Collaborative Review of Sterilization. Obstet Gynecol. 1999;93:889-895.
7. Trollice M. Fertility after tubal ligation – It's a matter of 'AGE'. ObGyn News, March 28, 2022.

## CULTURAL AND LINGUISTIC COMPETENCY & IMPLICIT BIAS

The California Medical Association (CMA) announced new standards for Cultural Linguistic Competency and Implicit Bias in CME. The goal of the standards is to support the role of accredited CME in advancing diversity, health equity, and inclusion in healthcare. These standards are relevant to ACCME-accredited, CMA-accredited, and jointly accredited providers located in California. AAGL is ACCME-accredited and headquartered in California.

CMA developed the standards in response to California legislation ([Business and Professions \(B&P\) Code Section 2190.1](#)), which directs CMA to draft a set of standards for the inclusion of cultural and linguistic competency (CLC) and implicit bias (IB) in accredited CME.

The standards are intended to support CME providers in meeting the expectations of the legislation. CME provider organizations physically located in California and accredited by CMA CME or ACCME, as well as jointly accredited providers whose target audience includes physicians, are expected to meet these expectations beginning January 1, 2022. AAGL has been proactively adopting processes that meet and often exceed the required expectations of the legislation.

CMA CME offers a variety of resources and tools to help providers meet the standards and successfully incorporate CLC & IB into their CME activities, including FAQ, definitions, a planning worksheet, and best practices. These resources are available on the [CLC and IB standards page](#) on the CMA website.

### **Important Definitions:**

**Cultural and Linguistic Competency (CLC)** – The ability and readiness of health care providers and organizations to humbly and respectfully demonstrate, effectively communicate, and tailor delivery of care to patients with diverse values, beliefs, identities and behaviors, in order to meet social, cultural and linguistic needs as they relate to patient health.

**Implicit Bias (IB)** – The attitudes, stereotypes and feelings, either positive or negative, that affect our understanding, actions and decisions without conscious knowledge or control. Implicit bias is a universal phenomenon. When negative, implicit bias often contributes to unequal treatment and disparities in diagnosis, treatment decisions, levels of care and health care outcomes of people based on race, ethnicity, gender identity, sexual orientation, age, disability and other characteristics.

**Diversity** – Having many different forms, types or ideas; showing variety. Demographic diversity can mean a group composed of people of different genders, races/ethnicities, cultures, religions, physical abilities, sexual orientations or preferences, ages, etc.

### **Direct links to AB1195 (CLC), AB241 (IB), and the B&P Code 2190.1:**

[Bill Text – AB-1195 Continuing education: cultural and linguistic competency.](#)

[Bill Text – AB-241 Implicit bias: continuing education: requirements.](#)

[Business and Professions \(B&P\) Code Section 2190.1](#)

### **CLC & IB Online Resources:**

[Diversity-Wheel-as-used-at-Johns-Hopkins-University-12.png \(850×839\) \(researchgate.net\)](#)

[Cultural Competence In Health and Human Services | NPIN \(cdc.gov\)](#)

[Cultural Competency – The Office of Minority Health \(hhs.gov\)](#)

[Implicit Bias, Microaggressions, and Stereotypes Resources | NEA](#)

[Unconscious Bias Resources | diversity.ucsf.edu](#)

[Act, Communicating, Implicit Bias \(racialequitytools.org\)](#)

<https://kirwaninstitute.osu.edu/implicit-bias-training>

<https://www.uptodate.com/contents/racial-and-ethnic-disparities-in-obstetric-and-gynecologic-care-and-role-of-implicitbiases>

<https://www.contemporaryobgyn.net/view/overcoming-racism-and-unconscious-bias-in-ob-gyn>

<https://pubmed.ncbi.nlm.nih.gov/34016820/>